Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Rating of “Moderate Buy” by Analysts

Akero Therapeutics, Inc. (NASDAQ:AKRO) has earned a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $46.83.

Several equities analysts have issued reports on the company. Citigroup assumed coverage on Akero Therapeutics in a research note on Monday, November 18th. They issued a “buy” rating and a $65.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a research note on Thursday.

Insider Activity

In related news, insider Catriona Yale sold 4,515 shares of the company’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $32.53, for a total transaction of $146,872.95. Following the completion of the sale, the insider now owns 74,158 shares in the company, valued at approximately $2,412,359.74. This represents a 5.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Andrew Cheng sold 108,366 shares of the company’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $31.73, for a total value of $3,438,453.18. Following the sale, the chief executive officer now owns 605,417 shares of the company’s stock, valued at $19,209,881.41. This trade represents a 15.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 262,135 shares of company stock worth $8,223,000 over the last quarter. 7.94% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Akero Therapeutics

Institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. grew its holdings in Akero Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after buying an additional 446 shares in the last quarter. Eastern Bank bought a new stake in Akero Therapeutics during the third quarter worth $100,000. Summit Financial Wealth Advisors LLC bought a new position in Akero Therapeutics in the 3rd quarter valued at $205,000. Victory Capital Management Inc. purchased a new stake in shares of Akero Therapeutics during the 3rd quarter valued at $211,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Akero Therapeutics during the 3rd quarter valued at $265,000.

Akero Therapeutics Price Performance

Akero Therapeutics stock opened at $25.14 on Monday. The stock’s 50 day moving average is $28.99 and its 200 day moving average is $27.99. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The firm has a market cap of $1.75 billion, a P/E ratio of -6.70 and a beta of -0.19. Akero Therapeutics has a one year low of $15.32 and a one year high of $37.00.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings data on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). As a group, research analysts expect that Akero Therapeutics will post -3.96 EPS for the current year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.